Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.

Khawaja M TalhaJennifer GreenGerasimos FilippatosStuart PocockFaiez ZannadMartina BrueckmannElke SchuelerAnne Pernille OfstadJoao Pedro FerreiraStefan D AnkerJaved Butler Julio RosenstockMilton Packer

Published in: Diabetes, obesity & metabolism (2024)

Empagliflozin exerts a consistent benefit on cardiovascular outcomes and renal function decline, irrespective of baseline insulin use, and reduces the need for sustained insulin initiation in patients with HF and diabetes.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
weight loss
adipose tissue
atrial fibrillation